Taysha Gene Therapies (Taysha Gene Therapies) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies COGS-to-Revenue?

Taysha Gene Therapies's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $3.60 Mil.

Taysha Gene Therapies's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Taysha Gene Therapies's Gross Margin % for the three months ended in Dec. 2023 was N/A%.

Taysha Gene Therapies COGS-to-Revenue Historical Data

The historical data trend for Taysha Gene Therapies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies COGS-to-Revenue Chart

Taysha Gene Therapies Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Taysha Gene Therapies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial												-	-	-	-	-

Taysha Gene Therapies COGS-to-Revenue Calculation

Taysha Gene Therapies's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	15.451
	=	0.00

Taysha Gene Therapies's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	3.604
	=	0.00

Taysha Gene Therapies (NAS:TSHA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Taysha Gene Therapies's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 3.604
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Taysha Gene Therapies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Taysha Gene Therapies (Taysha Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247

Website

https://www.tayshagtx.com

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Executives

Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long	director	KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam	officer: Chief Financial Officer	350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii	10 percent owner	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc.	10 percent owner	2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc.	10 percent owner	600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad	officer: CMO and Head of R&D	C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino	director	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape	director	C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235